Wockhardt Ltd is a prominent international pharmaceutical and biotechnology firm headquartered in Mumbai, India. The Business has manufacturing facilities in India, UK, Ireland, France and US, and Several other subsidiary companies in US, UK and France wocklean. It's currently a global company having over half of its sales coming from Europe. Its primary product collections are vaccines and cardiovascular medications.

Recently the Board of Directors have declared a new policy concerning the future of the organization's business in India and this relies in their revised opinion regarding the future outlook of the organization's business in India. This policy determines the Board to take decisions in respect of the organization's future growth strategy in India and abroad, taking under consideration the views of their stakeholders, for example, Government of India and the Indian private and public sector. The policy also lays out a strategy for the organization's activities in the pharmaceutical and bio-tech frontier regions of India. The majority of the shareholders have voted in favour of their policy, with only one shareholder contrary to the adoption of this policy.

Before the Company has produced several non-conformist pharmaceutical products for local and international markets, including insulin preparations and single dose dialysis machines. Some of those products have received orphan drug designation, or orphan drug's standing from the US Food and Drug Administration (FDA). The other drugs in this class obtained FDA Warning letters indicating potential concern for the security of the intended use in people.

As regards its activities in India and overseas, the Company has signed manufacturing agreements with the Food and Drug Administration of both India and the Wellcome Trust for the purposes of developing vaccines specifically for children with acute forms of the syndrome which affects the lungs, heart, kidneys and other major organs of the human body. These vaccines are being developed at the biopharmaceutical centre in India under license from the Indian pharmaceutical giant Cipla. The facility has also received clearance in the united kingdom government to manufacture therapeutic vaccines in the united kingdom.

A contract deal has been signed with the Indian pharmaceutical producer Vaxam for manufacture of vaccine stockpiled in the united kingdom for the benefit of children with Congenital Rubella, birth defects regarding the rubella virus and lotions wok syrup. A contract has been signed with the Indian pharmaceutical manufacturer Cipla for the production of vaccine stockpiled in the united kingdom for the purpose of fighting gastroenteritis, an intestinal infection due to Escherichia coli. A third contract with Cipla was signed to the supply of vaccine against meningococcal meningitis.

While approving its operations in wockhardt, the FDA concluded that the centers maintained adequate controls over the creation of the merchandise manufactured in the said facility. The FDA noted that it had conducted a set of quality evaluations of their centers throughout its visit. It was found that every one of the machines used for the production of contaminated vaccines were correctly preserved. There were no reports of unauthorized transfer of stocks in the center to any third party.